Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)

Gynecological Endocrinology

Volumn 33, Issue 1, 2017, Pages 39-42

  Fruzzetti, Franca ^a   Perini, Daria ^a   Russo, Marinella ^a   Bucci, Fiorella ^a   Gadducci, Angiolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

amenorrhea; Androgens; insulin resistance; insulin sensitizer; polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; GLUCOSE; HYDROCORTISONE; INOSITOL; INSULIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; ANTIDIABETIC AGENT; VITAMIN B COMPLEX;

ACNE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE TEST; HIRSUTISM; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; OUTCOME ASSESSMENT; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN RESISTANCE; METFORMIN; OUTCOME ASSESSMENT (HEALTH CARE); POLYCYSTIC OVARY SYNDROME; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84994175686     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590.2016.1236078     Document Type: Article

References (30)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
2. Diamanti-Kandarakis E., Polycystic ovarian syndrome:pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008;30:e3
3. Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883–96
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
5. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, et al. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007;18:280–5
6. González F, Rote NS, Minium J, et al. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab. Clin. Exp 2009;58:954–62
7. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410–15
8. Cussons AJ, Stuckey BGA, Watts GF., Cardiovascular disease in the polycystic ovary syndrome:new insights and perspectives. Atherosclerosis 2006;185:227–39
9. Randeva HS, Tan BK, Martin OW, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812–41
10. Baptiste CG, Battista MC, Trottier A, et al. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010;122:42–52
11. Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;16:CD007506
12. Nybacka Å, Carlstrom K, Stahle A, et al. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril 2011;96:1508–13
13. Baillargeon JP, Iuorno MJ, Nestler JE., Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–40
14. Glueck CJ, Streicher P, Wang P., Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002;3:1177–89
15. Bargiota A, Diamanti-Kandarakis E., The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 2012;3:27–47
16. Palomba S, Falbo A, Zullo F, et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome:a comprehensive review. Endocr Rev 2009;30:1–50
17. Thomas MP, Mills SJ, Potter BV., The “Other” inositols and their phosphates:synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl 2016;55:1614–50
18. Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome:a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–10
19. Dinicola S, Chiu TT, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 2014;54:1079–92
20. Di Paolo G, De Camilli P., Phosphoinositides in cell regulation and membrane dynamics. Nature 2006;7112:651–7
21. Thomas RM, Nechamen CA, Mazurkiewicz JE, et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology 2011;152:1691–701
22. Nestler E, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
23. Gerli S, Mignosa M, Di Renzo GC., Effects of inositol on ovarian function and metabolic factors in women with PCOS:a randomized double blind placebo controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–9
24. Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial:effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–54
25. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, authors. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
26. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
27. Matsuda M, DeFronzo RA., Insulin sensitivity indices obtained from oral glucose tolerance testing:comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70
28. Fruzzetti F, Ghiadoni L, Virdis A, et al. Adolescents with classical polycystic ovary syndrome have alterations in the surrogate markers of cardiovascular disease but not in the endothelial function. The possible benefits of metformin. J Pediatr Adolesc Gynecol 2016;pii:S1083-3188(16)30001-8
29. Lord JM, Flight IHK, Norman RJ., Metformin in polycystic ovary syndrome:systematic review and meta-analysis. BMJ 2003;327:951–6
30. Papaleo E, Unfer V, Baillargeon JP, et al. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009; 147:120–3